CHAIR
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

COCHAIRS
Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland*
Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX
Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY
Laura Pasqualucci, Columbia University Irving Comprehensive Cancer Center, New York, NY
Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

* - ICML Representative
[ R ] – recorded presentation with remote Q&A/discussion

WEDNESDAY, JUNE 19

Registration
3:30-8:30 P.M. | Liberty Foyer

Welcome and Opening Keynote Lecture
6-7 P.M. | Liberty B

6-6:10 Welcome and Introduction of Keynote Speaker
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

6:10-7 Metabolic regulation of lymphoma development
Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

Plenary Session 1: Signaling / Immune Synapse
7-8:45 P.M. | Liberty B
Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

7-7:05 Introduction
Francesco Bertoni

7:05-7:25 Oncogenic signaling in T-cell and B-cell lymphoma
Jürgen Ruland, Technical University of Munich, Munich, Germany

7:25-7:30 Discussion / Q&A

7:30-7:50 Lymphoma immune microenvironment shaping receptivity to various immunological therapeutic strategies
Roberta Zappasodi, Weill Cornell Medicine, New York, NY

7:50-7:55 Discussion / Q&A
7:55-8:15  Resistance mechanisms to BTK inhibitors
Francesco Bertoni

8:15-8:20  Discussion / Q&A

8:20-8:45  Panel Discussion / Q&A

Opening Reception
8:45-10:15 P.M. | Liberty A

THURSDAY, JUNE 20

Continental Breakfast
7:30-8:30 A.M. | Liberty A

Spotlight on Proffered Papers Session
8:30-9:55 A.M. | Liberty B
Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30-8:35  Introduction
Michael R. Green

8:35-8:46  EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions
Yusuke Isshiki, Weill Cornell Medicine, New York, NY

8:46-8:57  Aging-associated molecular and cellular alterations determine the biology and clinical characteristics of DLBCL in elderly patients
Nahuel Zamponi, Weill Cornell Medicine, New York, NY

8:57-9:08  Immunosurveillance of precancerous germinal center B cells
Dinis Pedro Parente Calado, The Francis Crick Institute, London, United Kingdom

9:08-9:19  Characterization of an essential MYC enhancer targeted by focal genomic alterations in diffuse large B-cell lymphoma
Aishwarya Gurumurthy, University of Michigan, Ann Arbor, MI

9:19-9:30  Single-cell transcriptomics reveals shared and subtype-specific vulnerabilities of the tumor-microenvironment ecosystems in peripheral T-cell lymphomas
Wen-Hsuan Wendy Lin, Columbia University Irving Medical Center, New York, NY
9:30-9:41  Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy
Xubin Li, The University of Texas MD Anderson Cancer Center, Houston, TX

9:41-9:52  SETD1B mutations confer apoptosis resistance and BCL2 independence in B-cell Lymphoma
Ana Portelinha, Memorial Sloan Kettering Cancer Center, New York, NY

Break
9:55-10:15 A.M. | Liberty Foyer

**Plenary Session 2: Germinal Center Biology and its Role in Lymphomagenesis**
10:15 A.M.-12 P.M. | Liberty B
Session Chair: Coraline Mlynarczyk, Weill Cornell Medicine, New York, NY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15-10:20</td>
<td>Introduction</td>
<td>Coraline Mlynarczyk</td>
<td>Weill Cornell Medicine, New York, NY</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Regulating programmed DNA lesions in B cells</td>
<td>Jayanta Chaudhuri</td>
<td>Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>10:40-10:45</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45-11:05</td>
<td>Competition in the germinal center</td>
<td>Coraline Mlynarczyk</td>
<td>Weill Cornell Medicine, New York, NY</td>
</tr>
<tr>
<td>11:05-11:10</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10-11:30</td>
<td>T-cell dependent acquisition of stem-like plasticity in Germinal Center B cells</td>
<td>Effie Apostolou</td>
<td>Weill Cornell Medicine, New York, NY</td>
</tr>
<tr>
<td>11:30-11:35</td>
<td>Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35-12</td>
<td>Panel Discussion / Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Free time / Lunch on own**
12-1:30 P.M.
Plenary Session 3: Premalignant Processes in Lymphomagenesis
1:30-3:15 P.M. | Liberty B
Session Chair: Jagan Muppidi, National Cancer Institute, Bethesda, MD

1:30-1:35  Introduction
Jagan Muppidi

1:35-1:55  Lymphoid clonal hematopoiesis and its relationship to monoclonal B-cell lymphocytosis
Aswin Sekar, Dana-Farber Cancer Institute, Boston, MA

1:55-2  Discussion / Q&A

2-2:20  Control of nutrient driven proliferation in mucosal germinal centers by the tumor suppressor GNA13
Jagan Muppidi

2:20-2:25  Discussion / Q&A

2:25-2:45  Expanded T cell clones with lymphoma driver somatic mutations in refractory celiac disease
Mandeep Singh, Garvin Institute of Medical Research, Sydney, Australia

2:45-2:50  Discussion / Q&A

2:50-3:15  Panel Discussion / Q&A

Break
3:15-3:35 P.M. | Liberty Foyer

Plenary Session 4: Lymphoma Clonal Precursors and Transformation
3:35-5:20 P.M. | Liberty B
Session Chair: Ari M. Melnick, Weill Cornell Medical College / Cornell University, New York, NY

3:35-3:40  Introduction
Ari M. Melnick

3:40-4  The elusive lymphoma clonal precursor cell
Ari M. Melnick

4-4:05  Discussion / Q&A

4:05-4:25  Deciphering and intercepting follicular lymphoma clonal precursor cells
Sandrine Roulland, Aix-Marseille University, Marseille, France

4:25-4:30  Discussion / Q&A
4:30-4:50  Transformation to aggressive lymphoma: Molecular basis and detection  
Erin M. Parry, Dana-Farber Cancer Institute, Boston, MA

4:50-4:55  Discussion / Q&A

4:55-5:20  Panel Discussion / Q&A

**Poster Session / Reception**
5:30-7:30 P.M. | Liberty A

**Evening off / Dinner on own**
7:30 P.M.-

**FRIDAY, JUNE 21**

**Continental Breakfast**
7:30-8:30 A.M. | Liberty A

**Plenary Session 5: Lymphoma Etiology and Outcomes- The Role of Age and Ethnicity**
8:30-10:15 A.M. | Liberty B
Session Chair: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX

8:30-8:35  Introduction  
Christopher R. Flowers

8:35-8:55  The etiology of pediatric lymphoma  
Lisa G. Roth, Weill Cornell Medicine, New York, NY
8:55-9  Discussion / Q&A

9-9:20  An aged/autoimmune origin to B cell lymphomas  
Leandro Venturutti, BC Cancer, Vancouver, BC, Canada
9:20-9:25  Discussion / Q&A

9:25-9:45  Disparities in lymphoma  
Christopher R. Flowers
9:45-9:50  Discussion / Q&A

9:50-10:15  Panel Discussion / Q&A

**Break**
10:15-10:35 A.M. | Liberty Foyer
Plenary Session 6: Lymphoma Epigenetics
10:35 A.M.-12:15 P.M. | Liberty B
Session Chair: Laura Pasqualucci, Columbia University, Institute of Cancer Genetics, New York, NY

10:35-10:40  Introduction
Laura Pasqualucci

10:40-11  Epigenetic therapies in T-cell lymphoma
Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY
11-11:05  Discussion / Q&A

11-11:20  Disentangling truncating and missense CREBBP mutations in B cell lymphoma
Laura Pasqualucci
11:20-11:25  Discussion / Q&A

11:25-11:45  Perturbation of cell state transitions by epigenetic mutations
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX
11:45-11:50  Discussion / Q&A

11:50-12:15  Panel Discussion / Q&A

Free time / Lunch on own
12:15-1:45 P.M.

Plenary Session 7: Lymphoma Microenvironment / Tumor Immunology of Lymphoma
1:45-3:30 P.M. | Liberty B
Session Chair: Margaret A. Shipp, Dana Farber Cancer Institute, Boston, MA

1:45-1:50  Introduction
Margaret A. Shipp

1:50-2:10  Bispecific antibodies in lymphoma therapy
Martin Hutchings, Copenhagen University Hospital, Copenhagen, Denmark
2:10-2:15  Discussion / Q&A

2:15-2:35  The lymphoma microenvironment
Margaret A. Shipp
2:35-2:40  Discussion / Q&A
2:40-3  Multi-omic profiling of the follicular lymphoma tumor microenvironment  
Andrea J. Radtke, National Institute of Allergy and Infectious Disease, Bethesda, MD
3-3:05  Discussion / Q&A

3:05-3:30  Panel Discussion / Q&A

Break
3:30-3:50 P.M.  | Liberty Foyer

Plenary Session 8: New Approaches in CAR T-cell Therapy
3:50-5:30 P.M.  | Liberty B
Session Chair: Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

3:50-3:55  Introduction  
Michel Sadelain

3:55-4:15  Logic gating of CAR T cells: OR and IF-BETTER  
Michel Sadelain
4:15-4:20  Discussion / Q&A

4:20-4:40  Clonotype-specific CAR T  
Marco Ruella, University of Pennsylvania, Philadelphia, PA
4:40-4:45  Discussion / Q&A

4:45-5:05  How to make CART cells work in spite of lymphoma immune evasion mechanisms  
Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, NY
5:05-5:10  Discussion / Q&A

5:10-5:30  Panel Discussion / Q&A

Evening off / Dinner on own
5:30 P.M. -

SATURDAY, JUNE 22

Continental Breakfast
7-8 A.M.  | Liberty A
Keynote Lecture
8-9 A.M. | Liberty B

8-8:05  Introduction of Keynote Speaker
       Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

8:05-9  Toward the noninvasive characterization of lymphomas & their microenvironments
       Ash A. Alizadeh, Stanford University, Stanford, CA

Plenary Session 9: Chemo-free Approaches to Lymphoma
9-10:45 A.M. | Liberty B
Session Chair: Jason Westin, The University of Texas MD Anderson Cancer Center, Houston, TX

9:00-9:05  Introduction
           Jason Westin

9:05-9:25  We will still use RCHOP in 2034?
           Jason Westin

9:25-9:30  Discussion / Q&A

9:30-9:50  Targeted treatment of DLBCL
           Christopher J. Melani, National Cancer Institute, Bethesda, MD

9:50-9:55  Discussion / Q&A

9:55-10:15  Rewiring cancer drivers to activate apoptosis
             Gerald R. Crabtree, Stanford University, Stanford, CA

10:15-10:20  Discussion / Q&A

10:20-10:45  Panel Discussion / Q&A

Break
10:45-11 A.M. | Liberty Foyer

Plenary Session 10: Bringing Genomics from Bench to Bedside
11 A.M.-12:45 P.M. | Liberty B
Session Chair: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, TX

11-11:05  Introduction
           Michael R. Green

11:05-11:25  Precision therapy based on somatic mutation profiles
              H. Christian Reinhardt, Essen University Hospital, Essen, Germany
11:25-11:30  Discussion / Q&A

11:30-11:50  T-cell lymphoma molecular classifications that inform therapy
Catalina Amador, University of Miami Miller School of Medicine, Miami, FL
11:50-11:55  Discussion / Q&A

11:55-12:15  [ R ] - Genetic subtype-guided immunochemotherapy in DLBCL
Wei-Li Zhao, Ruijin Hospital, Shanghai, China
12:15-12:20  Discussion / Q&A

12:20-12:45  Panel Discussion / Q&A

Departure
12:45 P.M.